Visceral fat and attribute-based medicine in chronic kidney disease

Front Endocrinol (Lausanne). 2023 Feb 9:14:1097596. doi: 10.3389/fendo.2023.1097596. eCollection 2023.

Abstract

Visceral adipose tissue plays a central role in obesity and metabolic syndrome and is an independent risk factor for both cardiovascular and metabolic disorders. Increased visceral adipose tissue promotes adipokine dysregulation and insulin resistance, leading to several health issues, including systemic inflammation, oxidative stress, and activation of the renin-angiotensin-aldosterone system. Moreover, an increase in adipose tissue directly and indirectly affects the kidneys by increasing renal sodium reabsorption, causing glomerular hyperfiltration and hypertrophy, which leads to increased proteinuria and kidney fibrosis/dysfunction. Although the interest in the adverse effects of obesity on renal diseases has grown exponentially in recent years, the relationship between obesity and renal prognosis remains controversial. This may be attributed to the long clinical course of obesity, numerous obesity-related metabolic complications, and patients' attributes. Multiple individual attributes influencing the pathophysiology of fat accumulation make it difficult to understand obesity. In such cases, it may be effective to elucidate the pathophysiology by conducting research tailored to individual attributes from the perspective of attribute-based medicine/personalized medicine. We consider the appropriate use of clinical indicators necessary, according to attributes such as chronic kidney disease stage, level of visceral adipose tissue accumulation, age, and sex. Selecting treatments and clinical indicators based on individual attributes will allow for advancements in the clinical management of patients with obesity and chronic kidney disease. In the clinical setting of obesity-related nephropathy, it is first necessary to accumulate attribute-based studies resulting from the accurate evaluation of visceral fat accumulation to establish evidence for promoting personalized medicine.

Keywords: attribute-based medicine; chronic kidney disease; obesity; patient-centered medicine; personalized medicine; precision medicine; sex difference; visceral fat.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Intra-Abdominal Fat / metabolism
  • Kidney / metabolism
  • Metabolic Syndrome* / metabolism
  • Obesity / metabolism
  • Renal Insufficiency, Chronic* / complications
  • Renal Insufficiency, Chronic* / metabolism

Grants and funding

This study was partly supported by a Grant-in-Aid for Intractable Renal Diseases Research and Research on Rare and Intractable Diseases, as well as by Health and Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare of Japan.